Sign Up Today and Learn More About Code Biotherapeutics Stock
Invest in or calculate the value of your shares in Code Biotherapeutics or other pre-IPO companies through EquityZen's platform.
Code Biotherapeutics Stock (COBI)
Code Biotherapeutics is a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies.
About Code Biotherapeutics Stock
Founded
2020
Headquarters
Hatfield, PA, US
Industries
Software, Artificial Intelligence, Data and Analytics
Code Biotherapeutics Press Mentions
Stay in the know about the latest news on Code Biotherapeutics
Enhanced targeting using antibody-oligonucleotide conjugates
patents • Feb 01, 2026
Enhanced dna dendrimers and methods of use thereof
patents • May 04, 2025
Enhanced dna dendrimers and methods of use thereof
patents • Apr 02, 2025
Nucleic acid carriers and therapeutic methods of use
patents • Apr 02, 2025
Nucleic acid carriers and therapeutic methods of use
patents • Feb 08, 2025
Code Biotherapeutics Management
Leadership team at Code Biotherapeutics
COO
Erin Brubaker
Chairman, Chief Executive Officer, and Co-Founder
Brian McVeigh
Join now and verify your accreditation status to gain access to:
- Code Biotherapeutics Current Valuation
- Code Biotherapeutics Stock Price
- Code Biotherapeutics Management
- Available deals in Code Biotherapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Code Biotherapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- Code Biotherapeutics Revenue and Financials
- Code Biotherapeutics Highlights
- Code Biotherapeutics Business Model
- Code Biotherapeutics Risk Factors
- Code Biotherapeutics Research Report from SACRA Research
Trading Code Biotherapeutics Stock
How to invest in Code Biotherapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Code Biotherapeutics through EquityZen funds. These investments are made available by existing Code Biotherapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Code Biotherapeutics stock?
Shareholders can sell their Code Biotherapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 420K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 51K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
